Table 1.

Construction and validation of immune-related risk score for predicting the disease-free survival of non-small cell lung cancer.

Variables	Univariate analysis		Training cohort		Testing cohort		Entire cohort
			Multivariate analysis		Multivariate analysis		Multivariate analysis
	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
Age	1.01 (1.00, 1.02)	0.055	1.01 (1.00, 1.03)	0.091	1.01 (0.99, 1.03)	0.431	1.01 (1.00, 1.03)	0.027
Sex
Male	Ref.		Ref.		Ref.		Ref.
Female	0.70 (0.54, 0.90)	0.005	0.72 (0.51, 1.00)	0.049	0.81 (0.47, 1.38)	0.437	0.74 (0.56, 0.96)	0.026
Tstage
T1	Ref.		Ref.		Ref.		Ref.
T2	1.05 (0.77, 1.41)	0.770	0.70 (0.48, 1.03)	0.073	1.24 (0.67, 2.28)	0.498	0.86 (0.64, 1.18)	0.354
T3	1.64 (1.16, 2.32)	0.005	1.63 (1.06, 2.52)	0.025	1.00 (0.47, 2.13)	0.991	1.18 (0.82, 1.70)	0.364
T4	2.85 (1.93, 4.22)	<0.001	2.30 (1.35, 3.94)	0.002	3.02 (1.38, 6.63)	0.006	2.27 (1.50, 3.44)	<0.001
Nstage
N0	Ref.		Ref.		Ref.		Ref.
N1	2.85 (2.03, 4.00)	<0.001	3.52 (2.27, 5.46)	<0.001	1.76 (0.83, 3.73)	0.138	2.91 (2.03, 4.18)	<0.001
N2	3.40 (2.56, 4.52)	<0.001	3.05 (2.11, 4.42)	<0.001	2.40 (1.35, 4.25)	0.003	3.00 (2.23, 4.03)	<0.001
Visceral pleural invasion
PL0	Ref.		Ref.		Ref.		Ref.
PL1	1.45 (1.11, 1.90)	0.006	1.14 (0.79, 1.65)	0.478	1.16 (0.69, 1.97)	0.579	1.12 (0.84, 1.50)	0.442
PL2	1.26 (0.76, 2.11)	0.370	1.58 (0.81, 3.06)	0.177	0.54 (0.16, 1.88)	0.334	1.21 (0.69, 2.12)	0.498
Vascular tumor emboli
No	Ref.		Ref.		Ref.		Ref.
Yes	2.05 (1.58, 2.65)	<0.001	1.43 (1.07, 1.92)	0.017	1.49 (0.86, 2.56)	0.152	1.36 (1.02, 1.79)	0.033
Resected lymph nodes	1.00 (0.98,1.01)	0.613	0.98 (0.97, 1.00)	0.015	0.98 (0.96, 1.01)	0.192	0.98 (0.97, 1.00)	0.012
Immune-related risk score
Low	Ref.		Ref.		Ref.		Ref.
Median	1.65 (1.21, 2.24)	0.001	1.94 (1.22, 3.08)	0.005	1.81 (1.02, 3.21)	0.044	1.62 (1.18, 2.23)	0.003
High	2.63 (1.86, 3.71)	<0.001	3.56 (2.06, 6.15)	<0.001	2.77 (1.59, 4.80)	<0.001	2.98 (2.02, 4.40)	<0.001